Chris Desira has joined Adalvo as Quality Management Systems (QMS) Manager, marking a new chapter in his career within the pharmaceutical sector.

“I’m pleased to share that I’ve recently joined Adalvo as QMS Manager,” he said. “I look forward to this new experience and to contributing within a leading B2B pharmaceutical company. Excited for the journey ahead.”

Mr Desira brings extensive experience in quality systems, with a strong background in GMP compliance, internal auditing, and corrective and preventive action (CAPA) frameworks. His career spans over a decade in the pharmaceutical industry, where he has held progressively senior roles across quality assurance and compliance functions.

Prior to joining Adalvo, he served as Head of Quality at Panaxia Pharmaceutical Industries, where he led quality operations and oversight. He previously held the role of Associate Director QA/QC within the same organisation.

Earlier in his career, Mr Desira spent over four years at Teva Pharmaceuticals in Malta, where he held multiple positions including Senior Quality Systems & Quality Compliance Specialist and Project Leader for the Nitrosamine Project, gaining experience in change management, regulatory compliance, and site-wide quality systems.

Alongside his corporate roles, he has also worked as a freelance GMP Quality Consultant, supporting pharmaceutical companies in strengthening compliance frameworks and preparing for regulatory inspections in line with EU GMP and ISO standards.

Mr Desira holds a Bachelor of Science in Chemistry and Biology from the University of Malta and a Master’s degree in Management from the University of Chester.

In his new role at Adalvo, he is expected to oversee and further develop the company’s quality management systems, supporting regulatory compliance and continuous improvement as the company expands its international operations.

Adalvo is involved in the generic pharmaceutical business-to-business segment. Headquartered in Malta and based at the Life Sciences Park, it is a partner to over 170 generic companies in more than 140 countries worldwide. Investment firm EQT took a majorit shareholding in Adalvo in 2025, saying it is committed to supporting Adalvo's "pivotal role to provide access to affordable healthcare to patients around the world."